Atlas Trials

ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)

Clinical trial NCT00439192 · TERMINATED

Trial details

NCT number
NCT00439192
Sponsor
elbion AG
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Overactive BladderUrinary Incontinence
Start date
2007-02-01
Enrollment
275

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.